Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6508 in Chinese Patients With SHPT
NCT05221008Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR6508 in secondary hyperparathyroidism (SHPT) (5 arms), sponsored by Hengrui Therapeutics. Primary endpoints: Time of maximum observed concentration, Maximum observed concentration and 6 more. Started Mar 2022; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT05221008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05221008.